Cargando…

Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling

AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenart, Lilla, Balogh, Dora B., Lenart, Nikolett, Barczi, Adrienn, Hosszu, Adam, Farkas, Tamas, Hodrea, Judit, Szabo, Attila J., Szigeti, Krisztian, Denes, Adam, Fekete, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647092/
https://www.ncbi.nlm.nih.gov/pubmed/31053872
http://dx.doi.org/10.1007/s00125-019-4888-z
_version_ 1783437653301002240
author Lenart, Lilla
Balogh, Dora B.
Lenart, Nikolett
Barczi, Adrienn
Hosszu, Adam
Farkas, Tamas
Hodrea, Judit
Szabo, Attila J.
Szigeti, Krisztian
Denes, Adam
Fekete, Andrea
author_facet Lenart, Lilla
Balogh, Dora B.
Lenart, Nikolett
Barczi, Adrienn
Hosszu, Adam
Farkas, Tamas
Hodrea, Judit
Szabo, Attila J.
Szigeti, Krisztian
Denes, Adam
Fekete, Andrea
author_sort Lenart, Lilla
collection PubMed
description AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we investigated the antidepressant effect and the mechanisms of action of the angiotensin receptor 1 blocker (ARB) losartan in an experiential model of diabetes-associated depression. METHODS: Experimental diabetes was induced by streptozotocin in adult male Wistar rats. After 5 weeks of diabetes, rats were treated for 2 weeks with a non-pressor oral dose of losartan (20 mg/kg). In protocol 1, cerebrovascular perfusion and glial activation were evaluated by single-photon emission computed tomography–MRI and immunohistochemistry. In protocol 2, behaviour studies were performed (forced swim test and open field test). Hippocampal proinflammatory response and brain-derived neurotrophic factor (BDNF) signalling were also assessed. RESULTS: Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan. This action of losartan occurs via changes in diabetes-induced neuroinflammatory responses rather than altered cerebral perfusion. We also show that as a part of its protective effect losartan restores BDNF production in astrocytes and facilitates BDNF–tropomyosin receptor kinase B–cAMP response element-binding protein signalling in the diabetic brain. CONCLUSIONS/INTERPRETATION: We identified a novel effect of losartan in the nervous system that may be implemented to alleviate symptoms of diabetes-associated depression. These findings explore a new therapeutic horizon for ARBs as possible antidepressants and suggest that BDNF could be a target of future drug development in diabetes-induced complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-019-4888-z) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-6647092
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-66470922019-08-06 Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling Lenart, Lilla Balogh, Dora B. Lenart, Nikolett Barczi, Adrienn Hosszu, Adam Farkas, Tamas Hodrea, Judit Szabo, Attila J. Szigeti, Krisztian Denes, Adam Fekete, Andrea Diabetologia Article AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we investigated the antidepressant effect and the mechanisms of action of the angiotensin receptor 1 blocker (ARB) losartan in an experiential model of diabetes-associated depression. METHODS: Experimental diabetes was induced by streptozotocin in adult male Wistar rats. After 5 weeks of diabetes, rats were treated for 2 weeks with a non-pressor oral dose of losartan (20 mg/kg). In protocol 1, cerebrovascular perfusion and glial activation were evaluated by single-photon emission computed tomography–MRI and immunohistochemistry. In protocol 2, behaviour studies were performed (forced swim test and open field test). Hippocampal proinflammatory response and brain-derived neurotrophic factor (BDNF) signalling were also assessed. RESULTS: Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan. This action of losartan occurs via changes in diabetes-induced neuroinflammatory responses rather than altered cerebral perfusion. We also show that as a part of its protective effect losartan restores BDNF production in astrocytes and facilitates BDNF–tropomyosin receptor kinase B–cAMP response element-binding protein signalling in the diabetic brain. CONCLUSIONS/INTERPRETATION: We identified a novel effect of losartan in the nervous system that may be implemented to alleviate symptoms of diabetes-associated depression. These findings explore a new therapeutic horizon for ARBs as possible antidepressants and suggest that BDNF could be a target of future drug development in diabetes-induced complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-019-4888-z) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2019-05-03 2019 /pmc/articles/PMC6647092/ /pubmed/31053872 http://dx.doi.org/10.1007/s00125-019-4888-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Lenart, Lilla
Balogh, Dora B.
Lenart, Nikolett
Barczi, Adrienn
Hosszu, Adam
Farkas, Tamas
Hodrea, Judit
Szabo, Attila J.
Szigeti, Krisztian
Denes, Adam
Fekete, Andrea
Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
title Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
title_full Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
title_fullStr Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
title_full_unstemmed Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
title_short Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
title_sort novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered bdnf signalling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647092/
https://www.ncbi.nlm.nih.gov/pubmed/31053872
http://dx.doi.org/10.1007/s00125-019-4888-z
work_keys_str_mv AT lenartlilla noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT baloghdorab noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT lenartnikolett noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT barcziadrienn noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT hosszuadam noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT farkastamas noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT hodreajudit noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT szaboattilaj noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT szigetikrisztian noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT denesadam noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling
AT feketeandrea noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling